Author

Simon Boyd

Observed name: Boyd, Simon

Institutions: Mahidol University, University of Oxford, Mahidol Oxford Tropical Medicine Research Unit

Observed institutions: Mahidol University, University of Oxford, Mahidol Oxford Tropical Medicine Research Unit

ORCID: 0009-0001-8731-5499

Observed ORCID: 0009-0001-8731-5499

OpenAlex ID: A5068047842

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

2023 · William H K Schilling, Podjanee Jittamala, et al. · The Lancet Infectious Diseases · 94

PDF

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

2024 · Viravarn Luvira, William H. K. Schilling, et al. · BMC Infectious Diseases · 32

PDF

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

2023 · Podjanee Jittamala, William H K Schilling, et al. · The Journal of Infectious Diseases · 27

PDF

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

2023 · William HK Schilling, Podjanee Jittamala, et al. · eLife · 22

PDF

The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis

2024 · Shivani Singh, Simon Boyd, et al. · Journal of Antimicrobial Chemotherapy · 20

PDF

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)

2024 · Phrutsamon Wongnak, William H K Schilling, et al. · The Lancet Infectious Diseases · 18

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

2025 · Podjanee Jittamala, Simon Boyd, et al. · EClinicalMedicine · 13

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

2022 · Podjanee Jittamala, William HK Schilling, et al. · medRxiv · 11

PDF

Nickel complexation and photophysics of alkylanthracenyl dioxocyclam macrocycle derivatives

2000 · Simon Boyd, Nuno M. Cabral, et al. · Australian Journal of Chemistry · 9

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

2025 · William H K Schilling, Podjanee Jittamala, et al. · The Lancet Infectious Diseases · 8

Evidence that remdesivir treatment reduces viral titers in patients with COVID-19

2024 · Simon Boyd, Shivani Singh, et al. · Antimicrobial Agents and Chemotherapy · 3

A comparison of national seasonal influenza treatment guidelines across the Asia Pacific region

2025 · Ellen Beer, Simon Boyd, et al. · PLOS Global Public Health · 2

Incidence and influencing factors of psychological problems among international travellers during quarantine

2023 · Simon Boyd, Wasin Matsee, et al. · Journal of Travel Medicine · 1

PDF

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19

2025 · William HK Schilling, Podjanee Jittamala, et al. · medRxiv

PDF

Author response: Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

2023 · William HK Schilling, Podjanee Jittamala, et al. · eLife

Works count: 20

Citation count: 381

H-index: 10

I10-index: 10